Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma

Among cisplatin-ineligible patients with untreated aUC, the observed clinical efficacy of combination EV+P is supported by a model of independent drug action. These findings suggest that distinct patient subgroups respond to EV and/or pembrolizumab. Identifying predictive biomarkers of response for each drug could reduce unnecessary toxicity arising from universal combination therapy, as patients could instead be selectively treated with whichever therapy is more likely to be effective.